Jonathan David Schwartz - 14 Feb 2022 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical Officer & Clinical Development, SVP. Exhibit 24: Power of Attorney
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Issuer symbol
RCKT
Transactions as of
14 Feb 2022
Net transactions value
$0
Form type
4
Filing time
16 Feb 2022, 20:02:50 UTC
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +81,010 $0.000000 81,010 14 Feb 2022 Common Stock 81,010 $20.00 Direct F1
transaction RCKT Restricted Stock Units Award $0 +25,984 $0.000000 25,984 14 Feb 2022 Common Stock 25,984 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 81,010 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

Chief Medical Officer & Clinical Development, SVP. Exhibit 24: Power of Attorney